1 Petersen RC, Negash S. Mild cognitive impairment:an overview[J]. CNS Spectr, 2008, 13:45-53.2 American Psychiatric Association. Diagnostic and statistical manual of mental disorder[M]. 4th ed. Washington DC:American Psychiatric Association, 1994:706-708.3 Sadun AA. The optic neuropathy of Alzheimer's disease[J]. Metab Pediatr Syst Ophthalmol, 1989, 12:64-68.4 Crow RW, Levin LB, LaBree L, et al. Sweep visual evoked potential evaluation of contrast sensitivity in Alzheimer's dementia[J]. Invest Ophthalmol Vis Sci, 2003, 44:875-878.5 Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia:diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology, 1993, 43:250-260.6 Pohjasvaara T, Mantyla R, Ylikoski R, et al. Comparison of different clinical criteria (DSM-Ⅲ, ADDTC, ICD-10, NINDS-AIREN, DSM-Ⅳ) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences[J]. Stroke, 2000, 31:2952-2957.7 中华神经科学会. 各类脑血管病诊断要点[J]. 中华神经科杂志, 1996, 29:379-3808 World Health Organization. Definition and diagnosis of diabetes mellitus an intermediate hyperglycemia:Report of a WHO/IDF consultation[R].Geneva, World Health Organization, 2006.9 Becker RC, Meade TW, Berger PB, et al. American College of Chest Physicians. The primary and secondary prevention of coronary artery disease:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)[J]. Chest, 2008, 133:776S-814S.10 Garber JR, Cobin RH, Gharib H. Clinical practice guidelines for hypothyroidism in adults:co-sponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association[J]. Endocr Pract, 2012 11:1-207.11 Laske C, Stransky E, Leyhe T, et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls[J]. J Psychiatr Res, 2007, 41:387-394.12 Nagata T, Shinagawa S, Nukariya K, et al. Association between BDNF Polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease[J]. Dement Geriatr Cogn Disord, 2012, 33:266-272.13 Yu H, Zhang Z, Shi Y, et al. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese han[J]. J Clin Psychiatry, 2008, 69:1104-1111.14 Woolley JD, Strobl EV, Shelly WB, et al. BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease[J]. Curr Alzheimer Res, 2012, 9:815-821.15 Forlenza OV, Diniz BS, Teixeira AL, et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment[J]. World J Biol Psychiatry, 2010, 11:774-780.16 Angelucci F, Spalletta G, di Iulio F, et al. Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels[J]. Curr Alzheimer Res, 2010, 7:15-20.17 宇辉, 张志, 施咏梅, 等. 遗忘型轻度认知损害临床诊断、神经心理学特征和BDNF血清水平及其基因多态性研究[G]. 第十一届全国神经病学学术会论文汇编. 长春, 2008:434-435.18 郁俊昌, 唐牟尼, 韩海英, 等. 阿尔茨海默病、血管性痴呆及轻度认知障碍患者血浆脑源性神经营养因子浓度变化[J]. 实用医学杂志, 2013, 29:1429-1431. |